-
AN-7
- names:
butyroyloxymethyl diethylphosphate
- CAS号:
213262-83-0
MDL Number: - MF(分子式): C9H19O6P MW(分子量): 254.21732
- EINECS: Reaxys Number:
- Pubchem ID: Brand:BIOFOUNT
| 货品编码 | 规格 | 纯度 | 价格 (¥) | 现价(¥) | 特价(¥) | 库存描述 | 数量 | 总计 (¥) |
|---|
| 中文别名 | AN-7 |
| 英文别名 | AN7; AN-7; AN 7; butyroyloxymethyl diethylphosphate |
| CAS号 | 213262-83-0 |
| Inchi | InChI=1S/C9H19O6P/c1-4-7-9(10)12-8-15-16(11,13-5-2)14-6-3/h4-8H2,1-3H3 |
| InchiKey | UGIGKLCVADLBRB-UHFFFAOYSA-N |
| 分子式 Formula | C9H19O6P |
| 分子量 Molecular Weight | 254.21732 |
| 溶解度Solubility | |
| 性状 | Solid powder |
| 储藏条件 Storage conditions | Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years). |
| 产品说明 | AN-7(CAS:213262-83-0):仅限应用于工业或者科学研究过程中非医疗目的,不应用于人类或动物的临床诊断以及治过程疗,该产品非药用,非食用。 |
| Introduction | AN-7 is a potent HDAC inhibitor, is also a prodrug of butyric acid, which induced histone hyperacetylation and differentiation and inhibited proliferation of human prostate 22Rv1 cancer cells in vitro and in vivo. AN-7 is likely to display a high therapeutic index and may be beneficial for prostate cancer patients. |
| Application1 | |
| Application2 | |
| Application3 |
| [1]Tarasenko N, Cutts SM, Phillips DR, Inbal A, Nudelman A, Kessler-Icekson G, Rephaeli A. Disparate impact of butyroyloxymethyl diethylphosphate (AN-7), a histone deacetylase inhibitor, and doxorubicin in mice bearing a mammary tumor. PLoS One. 2012;7(2):e31393. doi: 10.1371/journal.pone.0031393. Epub 2012 Feb 23. PubMed PMID: 22384017; PubMed Central PMCID: PMC3285631. |
| [2]Tarasenko N, Kessler-Icekson G, Boer P, Inbal A, Schlesinger H, Phillips DR, Cutts SM, Nudelman A, Rephaeli A. The histone deacetylase inhibitor butyroyloxymethyl diethylphosphate (AN-7) protects normal cells against toxicity of anticancer agents while augmenting their anticancer activity. Invest New Drugs. 2012 Feb;30(1):130-43. doi: 10.1007/s10637-010-9542-z. Epub 2010 Sep 23. PubMed PMID: 20862515. |
| [3] Tarasenko N, Nudelman A, Tarasenko I, Entin-Meer M, Hass-Kogan D, Inbal A, Rephaeli A. Histone deacetylase inhibitors: the anticancer, antimetastatic and antiangiogenic activities of AN-7 are superior to those of the clinically tested AN-9 (Pivanex). Clin Exp Metastasis. 2008;25(7):703-16. doi: 10.1007/s10585-008-9179-x. Epub 2008 May 28. PubMed PMID: 18506586. |
| [4] Blank-Porat D, Gruss-Fischer T, Tarasenko N, Malik Z, Nudelman A, Rephaeli A. The anticancer prodrugs of butyric acid AN-7 and AN-9, possess antiangiogenic properties. Cancer Lett. 2007 Oct 18;256(1):39-48. Epub 2007 Jul 3. PubMed PMID: 17611019. |
| [5] Engel D, Nudelman A, Levovich I, Gruss-Fischer T, Entin-Meer M, Phillips DR, Cutts SM, Rephaeli A. Mode of interaction between butyroyloxymethyl-diethyl phosphate (AN-7) and doxorubicin in MCF-7 and resistant MCF-7/Dx cell lines. J Cancer Res Clin Oncol. 2006 Oct;132(10):673-83. Epub 2006 Jul 7. PubMed PMID: 16826403. |
6: Rephaeli A, Blank-Porat D, Tarasenko N, Entin-Meer M, Levovich I, Cutts SM, Phillips DR, Malik Z, Nudelman A. In vivo and in vitro antitumor activity of butyroyloxymethyl-diethyl phosphate (AN-7), a histone deacetylase inhibitor, in human prostate cancer. Int J Cancer. 2005 Aug 20;116(2):226-35. PubMed PMID: 15800932.
对不起,暂无产品评价!
MSDS
SDS 1.0 中文
展开
SDS 1.0 英文
展开
- 相关产品
-
< >
- 推荐产品
-
< >
- 最新产品
-
< >
新闻
抱歉,暂无数据!


购物车 


